Immunovant, Inc. (NASDAQ:IMVT)
| Market Cap | 6.94B+98.9% |
| Revenue (ttm) | 7.09M |
| Net Income | -538.22M-20.3% |
| EPS | -2.82+1.1% |
| Shares Out | 206.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 962,188 |
| Open | 34.02 |
| Previous Close | 33.65 |
| Day's Range | 33.21 - 34.24 |
| 52-Week Range | 15.95 - 45.42 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 40.00(+18.98%) |
| Earnings Date | Nov 9, 2026 |
Immunovant, Inc. has a live Insider Score.
Scored on 0 qualifying trades from 0 insiders in the last 90 days.
About IMVT
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IMVT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IMVT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IMVT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IMVT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IMVT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IMVT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IMVT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $106.46M |
| VBVanguard Morningstar Small-Cap ETF | $77.08M |
| IWMiShares Russell 2000 ETF | $75.10M |
| XBIState Street SPDR S&P Biotech ETF | $72.84M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $44.37M |
| VXFVanguard Extended Market ETF | $36.62M |
Estimated from each fund’s disclosed top holdings × AUM
IMVT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IMVT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score